The promises and pitfalls of personalized health
Original reporting by The Verge
A routine waxing session took a surprising turn for senior reviewer Victoria Song when her esthetician revealed a global medical consensus: Polycystic Ovary Syndrome, or PCOS, would officially be renamed Polycystic Metabolic Ovarian Syndrome (PMOS). This seemingly minor change carries profound implications for the 170 million women worldwide affected by the condition. For years, the original name, with its focus on ovarian cysts, has obscured PMOS’s true nature as a complex hormonal and metabolic disorder, leading to misdiagnoses, inadequate research, and fragmented care. The new designation better reflects its wide-ranging impact, often manifesting without cysts and affecting multiple organ systems, including links to insulin resistance, type 2 diabetes, and cardiovascular disease.
The personal challenge
Yet, even with a more accurate name, PMOS remains profoundly individualized. Song’s own decade-long journey managing the condition illustrates this starkly: while she experiences insulin resistance and hirsutism, her esthetician battles cystic acne and ovarian cysts, with varying responses to treatments like Metformin or intermittent fasting. This highly variable experience casts a critical light on the burgeoning health tech trend promising "personalized health." Companies are increasingly touting AI-driven insights and tailored recommendations based on individual data, but Song argues that for those with complex, non-standard health profiles, the reality often falls short. Current algorithms frequently overlook critical factors like hormonal birth control or metabolic differences, leaving users to painstakingly adapt and curate their own ad-hoc solutions. The promise of effortless, individualized care, it seems, is still largely aspirational.
The renaming of polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) stands as a stark reminder of the long, incremental journey required to accurately understand and categorize complex human conditions. This slow, deliberate progress in medicine contrasts sharply with the rapid development and marketing of "personalized health" technologies. While the allure of tailored insights from our own biometric data is compelling, the author's experience with PMOS reveals a significant chasm between this promise and present-day reality. Current AI-driven recommendations frequently fail to account for specific diagnoses, medication interactions, or fundamental metabolic differences unique to individuals, often forcing users to become their own chief data scientists, medical researchers, and self-trainers for their devices. This gap underscores a critical disconnect between technological ambition and the intricate biological nuances that define diverse human health.